首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1490030

全球慢性阻塞性肺病(COPD) 治療市場：依藥物類別、給藥途徑、通路及地區分類

Global Chronic Obstructive Pulmonary Disease Treatment Market, By Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Corticosteroids, Others), By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年05月22日 | 出版商:

Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球慢性阻塞性肺病（COPD）治療市場估計2024年為192.1億美元，預計2031年將達到283.7億美元，2024年至2031年的年複合成長率為5.7%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	192.1億美元
實際資料	2019年至2023年	預測期	從2024年到2031年
預測2024-2031年年複合成長率：	5.70%	2031年價值預測	283.7億美元

圖：2024年依地區分類的慢性阻塞性肺病（COPD）治療市場佔有率（%）

慢性阻塞性肺病（COPD）是指導致氣流阻塞和呼吸相關問題的肺部疾病。包括肺氣腫和慢性支氣管炎。慢性阻塞性肺病的主要原因包括吸菸、職場時接觸肺部刺激物（如灰塵和煙霧）以及空氣污染。 COPD 的主要症狀包括呼吸短促、咳嗽、產生黏液（痰）和喘息。隨著慢性阻塞性肺病的進展，肺功能會隨著時間的推移而下降，導致呼吸困難。

市場動態：

全球慢性阻塞性肺病（COPD）治療市場的成長是由吸菸率高、全球空氣污染程度上升、老年人口增加以及對該疾病和可用治療方案認知的提高所推動的。然而，缺乏對慢性阻塞性肺病和肺癌等相關併發症的完整治療方法可能會阻礙市場成長。製藥公司投資研發治療慢性阻塞性肺病的新型生物製藥，這能為市場成長提供有利的機會。該公司開發腎上腺素自動注射器、支氣管擴張劑、吸入性皮質類固醇和聯合治療，以有效治療慢性阻塞性肺病症狀和病情惡化。

本研究的主要特點

本報告詳細分析了全球慢性阻塞性肺病（COPD）治療市場，包括市場規模（十億美元）和年複合成長率（CAGR%）。
揭示了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點，實績和策略等參數，對全球慢性阻塞性肺病（COPD）治療市場的主要企業進行概況分析。
主要企業包括AstraZeneca、Orion Corporation、Mylan NV、Teva Pharmaceutical Industries Ltd.、GSK plc、Novartis AG、Sunovion Pharmaceuticals, Inc、CHIESI Farmaceutici SpA、Alembic Pharmaceuticals Ltd、Verona Pharmaceuticals、Theravance Biopharma Ltd、Sanofi、Boehringer Ingelheim International GmbH、Merck &Co.、Grifols, SA、Almirall, SA、Genentech, Inc.
本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球慢性阻塞性肺病（COPD）治療市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球慢性阻塞性肺病（COPD）治療市場的各種策略矩陣來促進他們的決策。

公司簡介
- AstraZeneca
- Orion Corporation
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Novartis AG
- Sunovion Pharmaceuticals, Inc.
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- F. Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck &Co., Inc
- Grifols, SA
- Almirall, SA
- Genentech, Inc

第10章分析師建議

Wheel of Fortune
分析師觀點
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI2656

Global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at USD 19.21 Bn in 2024 and is expected to reach USD 28.37 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 19.21 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	5.70%	2031 Value Projection:	US$ 28.37 Bn

Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region, 2024

Global Chronic Obstructive Pulmonary Disease Treatment Market - IMG1

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

By Drug Class:
- Bronchodilators
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Corticosteroids
- Others
By Route of Administration:
- Oral
- Inhalation
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca
- Orion Corporation
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Novartis AG
- Sunovion Pharmaceuticals, Inc.
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc
- Grifols, S.A.
- Almirall, S.A
- Genentech, Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Epidemiology
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Inhalation
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- AstraZeneca*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Orion Corporation
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GSK plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sunovion Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- F. Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc
- Grifols, S.A.
- Almirall, S.A
- Genentech, Inc